The FDA's action on Seldane leaves you in an awkward position

February 1997

    The FDA's action on Seldane leaves you in an awkward position.

    There have been hundreds of reports of arrhythmias and sudden death associated with Seldane (terfenadine). The FDA says it's no longer worth the risk...now that Allegra is on the market.

    Allegra (fexofenadine) is the active metabolite of Seldane...it's just as effective, but without the cardiac risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote